![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessErratum: DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia
Correction to: Oncogene (2016) 35, 3079–3082; doi:10.1038/onc.2015.359; published online 5 October 2015 Updated online 13 March 2017: This article was originally published under a CC BY-NC-ND 4.0 license, but ...
-
Article
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis
Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is repor...
-
Article
Open AccessDNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia
Close to half of de novo acute myeloid leukemia (AML) cases do not exhibit any cytogenetic aberrations. In this regard, distortion of the DNA methylation setting and the presence of mutations in epigenetic modifi...
-
Article
Open AccessEpimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia
Mutations in the genetic sequence of the DNA de novo methyltransferase DNMT3A (DNA methyltransferase 3A) are found in many patients with acute myeloid leukemia (AML). They lead to dysfunction of DNMT3A protein an...
-
Article
Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR–ABL-positive cells
Persistent activation of the Abl tyrosine kinase in the BCR–ABL fusion protein is the major cause of chronic myeloid leukemia (CML). Among many other substrates BCR–ABL phosphorylates STAT5 and Src family kina...
-
Article
Hypercholesterolemia and its association with enhanced stem cell mobilization and harvest after high-dose cyclophosphamide+G-CSF
High-dose chemotherapy with autologous peripheral blood SCT is a common treatment option in several hematological and non-hematological malignancies. So far, prediction of successful stem cell mobilization and...
-
Article
SOCS2: inhibitor of JAK2V617F-mediated signal transduction
Janus kinase 2 (JAK2)V617F-activating mutations (JAK2mu) occur in myeloproliferative disorders (MPDs) and myelodysplastic syndromes (MDSs). Cell lines MB-02, MUTZ-8, SET-2 and UKE-1 carry JAK2V617F and derive fro...
-
Article
Contrast enhancement in multidetector-row computed tomography (MDCT) of the abdomen: intraindividual comparison of contrast media containing 300 mg versus 370 mg iodine per ml
The purpose of this study was to intraindividually evaluate the difference in intraluminal vessel and parenchyma contrast enhancement of two different iodine concentrations in multidetector-row computed tomogr...
-
Article
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
An acquired autoactivating mutation with a V617F amino-acid substitution in the JAK2 tyrosine kinase is frequently found in BCR/ABL-negative myeloproliferative disorders (MPD). Hypermethylation of CpG islands wit...
-
Article
DNA methylation changes in multiple myeloma
Using a candidate gene approach, we analyzed the methylation status of the promoter-associated CpG islands of 11 well-characterized tumor suppressor genes by methylation-specific polymerase chain reaction in f...
-
Article
Remission of severe cold agglutinin disease Rituximab therapy